

Curis Inc (CRIS) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/CFF2C6F37D7EN.html>

Date: July 2021

Pages: 48

Price: US\$ 125.00 (Single User License)

ID: CFF2C6F37D7EN

Abstracts

Curis Inc (CRIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating cancers with substantial unmet medical need. The company's lead product Erivedge has been developed in collaboration with F. Hoffmann-La Roche Ltd and Genentech, which is commercialized for the treatment of advanced basal cell carcinoma (BCC). The product is approved for use in patients with advanced BCC in the US, European Union (EU), Australia and several other countries.

Curis has four drug candidates in development, Fimepinostat (previously CUDC-907) for treating diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-170 for advanced solid tumors or lymphoma; CA-4948 for treating non-Hodgkin lymphomas, and CI-8993 a human IgG1 kappa monoclonal antibody directed against VISTA including PD-1 and PD-L1 for treatment of cancer. Curis is headquartered in Lexington, Massachusetts, the US.

Curis Inc Key Recent Developments

Jun 25,2021: Curis Set to Join Russell 2000, 3000 and Microcap Indexes

May 12,2021: Curis Reports First Quarter 2021 Financial Results

May 05,2021: Curis to Release First Quarter 2021 Financial Results and Hold

Conference Call on May 12, 2021

Apr 28,2021: Curi Announces New Chief Operating Officer for Insurance Solutions Business

Apr 06,2021: Curis to Present at 20th Annual Needham Virtual Healthcare Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Curis Inc - Key Facts
Curis Inc - Key Employees
Curis Inc - Key Employee Biographies
Curis Inc - Major Products and Services
Curis Inc - History
Curis Inc - Company Statement
Curis Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Curis Inc - Business Description
R&D Overview
Curis Inc - SWOT Analysis
SWOT Analysis - Overview
Curis Inc - Strengths
Curis Inc - Weaknesses
Curis Inc - Opportunities
Curis Inc - Threats
Curis Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Curis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Curis Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 12, 2021: Curis Reports First Quarter 2021 Financial Results

May 05, 2021: Curis to Release First Quarter 2021 Financial Results and Hold
Conference Call on May 12, 2021

Apr 28, 2021: Curi Announces New Chief Operating Officer for Insurance Solutions
Business

Apr 06, 2021: Curis to Present at 20th Annual Needham Virtual Healthcare Conference

Mar 16, 2021: Curis Reports Fourth Quarter and Year-End 2020 Financial Results

Mar 09, 2021: Curis to Release Fourth Quarter 2020 Financial Results and Hold
Conference Call on March 16, 2021

Mar 02, 2021: Curis to Present at H.C. Wainwright & Co. Global Life Sciences
Conference

Feb 19, 2021: Curis to Present at SVB Leerink 10th Annual Global Healthcare
Conference

Nov 10, 2020: Curis reports third quarter 2020 financial results

May 12, 2020: Curis reports first quarter 2020 financial results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Curis Inc, Key Facts
Curis Inc, Key Employees
Curis Inc, Key Employee Biographies
Curis Inc, Major Products and Services
Curis Inc, History
Curis Inc, Subsidiaries
Curis Inc, Key Competitors
Curis Inc, Ratios based on current share price
Curis Inc, Annual Ratios
Curis Inc, Annual Ratios (Cont...1)
Curis Inc, Interim Ratios
Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Curis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Curis Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Curis Inc, Performance Chart (2016 - 2020)

Curis Inc, Ratio Charts

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Curis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Curis Inc (CRIS) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/CFF2C6F37D7EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CFF2C6F37D7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970